Tinzaparin (Innohep)

A low-molecular-weight heparin with anticoagulant properties that is used in the prevention and treatment of VENOUS THROMBOEMBOLISM, and to prevent clotting during EXTRACORPOREAL CIRCULATION.

Also Known As:

Networked: 223 relevant articles (37 outcomes, 84 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Mousa, Shaker A: 11 articles (03/2018 - 01/2002)
2.	Bath, Philip M W: 9 articles (10/2012 - 09/2005)
3.	Leys, Didier: 9 articles (10/2012 - 09/2005)
4.	Meyer, Guy: 8 articles (01/2022 - 12/2012)
5.	O'Neill, Desmond: 8 articles (10/2012 - 07/2006)
6.	TAIST Investigators: 8 articles (10/2012 - 03/2006)
7.	De Deyn, Peter Paul: 7 articles (10/2012 - 07/2006)
8.	Gray, Laura J: 7 articles (10/2012 - 09/2005)
9.	Hull, Russell D: 6 articles (09/2013 - 12/2003)
10.	Sprigg, Nikola: 6 articles (10/2012 - 09/2005)

Related Diseases

1.	Neoplasms (Cancer) 09/07/2021 - "Further studies are required to determine whether weight adjusted doses of Tinzaparin may provide more effective prophylaxis following gynaecological cancer surgery." 07/01/2018 - "The aim of this article was to study the pharmacological properties and effectiveness of tinzaparin in patients with cancer as well as its potential anticancer properties. " 04/01/2016 - "We conducted a single arm phase 2 study to evaluate the efficacy and safety of once daily tinzaparin for the initial treatment and extended prophylaxis of VTE in cancer patients. " 02/01/2004 - "Subgroup analyses from these studies and preclinical experiments suggested a role for tinzaparin in patients with malignancy who are at high risk for thromboembolic complications. " 08/01/2022 - "Intermediate dose of tinzaparin seems to be an appropriate agent for cancer-associated thromboprophylaxis management. "
2.	Venous Thrombosis (Deep-Vein Thrombosis) 03/01/2003 - "Low molecular weight heparins, specially tinzaparin, are a safe and effective treatment for deep vein thrombosis in our unit." 10/01/2007 - "Phase 1 of the study identified criteria for the safe discharge of selected patients; phase 2 treated a cohort of low-risk patients with PE as outpatients with tinzaparin using existing deep venous thrombosis services. " 10/01/2009 - "One patient developed a deep venous thrombosis while taking tinzaparin, and three patients developed thromboembolic complications while off tinzaparin. " 01/01/2008 - "Twenty-two pregnant patients with a confirmed deep venous thrombosis were treated with tinzaparin either in a once- or twice-daily regimen. " 09/01/2007 - "Tinzaparin in long-term treatment of deep venous thrombosis."
3.	Ischemic Stroke 10/01/2012 - "Quality of life after ischemic stroke varies in western countries: data from the tinzaparin in Acute Ischaemic Stroke Trial (TAIST)." 11/01/2007 - "We used data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST) to assess the relationship between sex and QoL after ischemic stroke. " 03/01/2006 - "All 1484 patients from 11 countries who were enrolled into the tinzaparin in acute ischaemic stroke trial (TAIST) were included in this substudy. " 03/01/2006 - "Significant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST)." 02/01/2011 - "Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST)."
4.	Pulmonary Embolism 06/01/2020 - "Case 2: a 71-year-old woman hospitalised for pulmonary embolism was given tinzaparin. " 01/01/2004 - "In the initial treatment of acute proximal DVT and pulmonary embolism, SC tinzaparin 175 anti-Xa IU/kg/day was at least as effective as adjusted-dosage intravenous (IV) UFH. " 10/27/2001 - "Tinzaparin reduced health care costs for pulmonary embolism due to easier administration, less complex laboratory tests, and personnel time savings. " 10/27/2001 - "[Economic assessment of the use of tinzaparin in the treatment of acute pulmonary embolism in France]." 04/01/1998 - "Additionally, tinzaparin is licensed for the treatment of pulmonary embolism (PE). "
5.	Venous Thromboembolism 08/01/2002 - "Tinzaparin may also be effective for unlabeled uses, such as prophylaxis of venous thromboembolism (VTE) after orthopedic, general, and abdominal surgery, although more data are needed to define the optimal dose for this indication. " 01/01/2023 - "Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study." 06/01/2019 - "Treatment of venous thromboembolism with tinzaparin in oncological patients." 02/01/2018 - "National guidelines have been developed to ensure correct dosing of tinzaparin for women delivered by caesarean delivery (CD) to reduce the risk of venous thromboembolism. " 12/01/2011 - "Endpoints were presented using descriptive statistics for all pregnancies, and by reason for tinzaparin use (treatment of venous thromboembolism [VTE] and prophylaxis). "

Related Drugs and Biologics

1.	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
2.	Enoxaparin (Lovenox)
3.	Heparin (Liquaemin)
4.	Aspirin (Acetylsalicylic Acid)
5.	Tinzaparin (Innohep)
6.	Anticoagulants
7.	Warfarin (Coumadin)
8.	Nadroparin (Nadroparin Calcium)
9.	Dalteparin (Dalteparin Sodium)
10.	Vitamin K

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Central Venous Catheters
4.	Arthroplasty
5.	Hip Replacement Arthroplasty (Total Hip Replacement)